Daphne Kluitmans2026-09-04T16:25:33+02:00 Case study – Cellular sensitivity to WRN inhibition in colony-forming unit assay Case study – Cellular sensitivity to WRN inhibition in colony-forming unit assay Case study – Cellular sensitivity to WRN inhibition in colony-forming unit assay
Daphne Kluitmans2026-09-04T16:26:36+02:00 Case study – Fluorescence imaging of DNA damage after WRN inhibitor exposure Case study – Fluorescence imaging of DNA damage after WRN inhibitor exposure Case study – Fluorescence imaging of DNA damage after WRN inhibitor exposure
Daphne Kluitmans2026-09-04T16:27:02+02:00 Case study – High TTK expression in uterine corpus endometrial carcinoma Case study – High TTK expression in uterine corpus endometrial carcinoma Case study – High TTK expression in uterine corpus endometrial carcinoma
Daphne Kluitmans2026-09-04T16:27:31+02:00 Case study – Downstream effects of specific TP53 mutations Case study – Downstream effects of specific TP53 mutations Case study – Downstream effects of specific TP53 mutations
yvonne2026-09-04T16:29:29+02:00 Case study – Prediction of ABC transporter-mediated drug resistance through gene expression analysis Case study – Prediction of ABC transporter-mediated drug resistance through gene expression analysis Case study – Prediction of ABC transporter-mediated drug resistance through gene expression analysis
yvonne2026-09-04T16:29:56+02:00 Case study – PROTAC-induced degradation of cancer immunotherapy target IDO1 Case study – PROTAC-induced degradation of cancer immunotherapy target IDO1 Case study – PROTAC-induced degradation of cancer immunotherapy target IDO1
Oncolines®2026-09-04T16:30:20+02:00 Case study – Stepwise, in-depth cancer gene mutation analysis reveals cellular targeting of KRAS mutant-selective inhibitors Case study – Stepwise, in-depth cancer gene mutation analysis reveals cellular targeting of KRAS mutant-selective inhibitors Case study – Stepwise, in-depth cancer gene mutation analysis reveals cellular targeting of KRAS mutant-selective inhibitors
janneke2026-09-04T16:30:52+02:00 Case study – Target validation by combining Oncolines® profiling and gene dependency screens Case study – Target validation by combining Oncolines® profiling and gene dependency screens Case study – Target validation by combining Oncolines® profiling and gene dependency screens
Oncolines®2026-09-04T16:31:17+02:00 Case study – Protein expression analysis identifies predictive drug-response markers for the MEK inhibitor trametinib Case study – Protein expression analysis identifies predictive drug-response markers for the MEK inhibitor trametinib Case study – Protein expression analysis identifies predictive drug-response markers for the MEK inhibitor trametinib
Oncolines®2026-09-04T16:31:44+02:00 Case study – Target identification via Oncolines® profiling and ResidenceTimer™ Case study – Target identification via Oncolines® profiling and ResidenceTimer™ Case study – Target identification via Oncolines® profiling and ResidenceTimer™
janneke2026-09-04T16:32:59+02:00 Case study – Gene expression profiling to understand and combat drug resistance Case study – Gene expression profiling to understand and combat drug resistance Case study – Gene expression profiling to understand and combat drug resistance
Oncolines®2026-09-04T16:33:49+02:00 Case study – Combination matrix to determine Bliss independence synergy scores Case study – Combination matrix to determine Bliss independence synergy scores Case study – Combination matrix to determine Bliss independence synergy scores
yvonne2026-09-04T16:34:11+02:00 Case study – 3D spheroid drug sensitivity Case study – 3D spheroid drug sensitivity Case study – 3D spheroid drug sensitivity
Oncolines®2026-09-07T13:16:03+02:00 Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer
Oncolines®2026-09-04T16:35:37+02:00 Case study – Synergistic interaction of olaparib and cisplatin Case study – Synergistic interaction of olaparib and cisplatin Case study – Synergistic interaction of olaparib and cisplatin
Oncolines®2026-09-04T16:36:29+02:00 Case study – TTK patient stratification marker Case study – TTK patient stratification marker Case study – TTK patient stratification marker
Oncolines®2024-11-19T12:54:57+01:00 Case study – MEK inhibitor Case study – MEK inhibitor Case study – MEK inhibitor
Oncolines®2024-11-19T12:57:31+01:00 Case study – Kadcyla® Case study – Kadcyla® Case study – Kadcyla®
yvonne2026-09-04T16:28:59+02:00 Case study – Binding kinetics of TROP2-targeted ADCs and antibodies via ResidenceTimer™ Case study – Binding kinetics of TROP2-targeted ADCs and antibodies via ResidenceTimer™ Case study – Binding kinetics of TROP2-targeted ADCs and antibodies via ResidenceTimer™
Oncolines®2026-09-04T16:31:44+02:00 Case study – Target identification via Oncolines® profiling and ResidenceTimer™ Case study – Target identification via Oncolines® profiling and ResidenceTimer™ Case study – Target identification via Oncolines® profiling and ResidenceTimer™
Oncolines®2026-09-04T16:34:35+02:00 Case study – BTK inhibitor fenebrutinib Case study – BTK inhibitor fenebrutinib Case study – BTK inhibitor fenebrutinib
Oncolines®2026-09-04T16:36:55+02:00 Case study – Arginase-1 Inhibitors Case study – Arginase-1 Inhibitors Case study – Arginase-1 Inhibitors
Oncolines®2026-09-04T16:37:25+02:00 Case study – Characterization of TTK Inhibitors Case study – Characterization of TTK Inhibitors Case study – Characterization of TTK Inhibitors
Oncolines®2026-09-04T16:37:49+02:00 Case study – BTK Inhibitor ibrutinib Case study – BTK Inhibitor ibrutinib Case study – BTK Inhibitor ibrutinib
